SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms...
34 insider purchases on record · latest filing 2025-11-21.
Insiders have also filed 8 sale transactions at SLS.